In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Second financing in a month brings in another $11.28mm for Xoma

Executive Summary

Just weeks after netting $9.4mm, Xoma has closed on another private sale of shares. This time it netted $11.28mm through the registered direct offering of 10.4mm units to certain institutional investors at $1.15 each (a 40% premium). The units consist of one common share and a five-and-a-half-year warrant to buy half of a share (up to 5.2mm shares at $1.30 apiece). The proceeds will be used to continue developing XOMA052, an anti-IL-1 beta antibody. Canaccord Adams and Wedbush PacGrow Life Sciences were the placement agents.
Deal Industry
  • Pharmaceuticals
  • Biotechnology
    • Drug Discovery Tools
    • Synthesis Technologies, Production Processes
    • Large Molecule
      • Antibodies
Deal Status
  • Final
Deal Type
  • Financing
    • Private Investment in Public Equity
    • Private Placement

Related Companies